Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Elez, Salah Eddin Al-Batran, Patrick M. Boland, Todd Crocenzi, Chloe E. Atreya, Yi Cui, Tong Dai, Patricia MarinelloLuis A. Diaz, Thierry André

Research output: Contribution to journal › Article › peer-review

143 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164'. Together they form a unique fingerprint.

Medicine & Life Sciences